4 Healthcare Stock Stories Prescribed For Investors

Chembio Diagnostics (NASDAQ:CEMI): Closing price $4.50

Chembio announced Thursday that it has won a cooperative research agreement with a United States government agency for as much as $750,000 for an eight-month development project. The company will develop rapid POC diagnostic tests for five infectious diseases linked with febrile illness, and to multiplex them into a single assay. The test would be optimized for employment with a mobile reader that incorporates cell phone tech to enable the results to be recorded, transmitted and monitored remotely by means of a cloud system, in real-time.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CEMI

Forest Laboratories (NYSE:FRX): Closing price $39.53

On Thursday, Forest said that Chief Executive and President Howard Solomon will retire, effective December 31st. Pursuant to the same nominating and election processes as all directors, Solomon is expected to remain as chairman through the 2014 Annual General Meeting, at which time another chairman will be selected. Solomon will keep the title of chairman emeritus after the 2014 meeting and has agreed to serve as senior adviser to the firm after his retirement as CEO and President.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

FRX

InspireMD (NASDAQ:NSPR): Closing price $2.20

InspireMD has announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial showing that the MGuard Embolic Protection Stent outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction patients. Results from the trial will be presented at the InspireMD STEMI Symposium at EuroPCR, which is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions in Paris from May 21st through the 24th.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

NSPR

Celgene Corporation (NASDAQ: CELG): Closing price $123.71

Celgene Corporation’s subsidiary Celgene International Sàrl, on Thursday announced that the FDA has assigned a priority review designation to the supplemental New Drug Application for the use of Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the firstline treatment of patients suffering from advanced pancreatic cancer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CELG

Don’t Miss: Is Romneycare an Accurate Reflection of Obamacare’s Future?

More Articles About:    

More from The Cheat Sheet